A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
详细信息 查看全文
- 作者：Noa Biran1 ; Scott D. Rowley1 ; srowley@hackensackumc.org" class="auth_mail" title="E-mail the corresponding author ; David H. Vesole1 ; Shijia Zhang2 ; Michele L. Donato1 ; Joshua Richter1 ; Alan P. Skarbnik1 ; Andrew Pecora1 ; David S. Siegel1
- 关键词：Peripheral blood autologous stem cell transplantation ; Multiple myeloma ; Melphalan ; Bortezomib
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：22
- 期：12
- 页码：2165-2171
- 全文大小：561 K
文摘
- •
Escalating doses of bortezomib with high-dose melphalan were evaluated with stem cell rescue for multiple myeloma
- •
Thirty-two patients were enrolled; 14 received bortezomib with high-dose melphalan as a second of tandem and 18 as a salvage autologous stem cell transplantation
- •
Bortezomib with high-dose melphalan autologous stem cell transplantation was well tolerated without emergent or increasing peripheral neuropathy.
- •
The most common grade 3 or 4 nonhematologic adverse events were neutropenic fever (25%) and nausea (18.8%)
- •
Two-year overall survival and progression-free survival were 76% and 39%, respectively, with a median follow-up of 31.7 months.